[AntiEBV activity of 6-azacytidine and its derivatives].
Epstein-Barr virus (EBV) causes several lymphoproliferative diseases, lesions of the central and peripheral nervous systems. Spectrum of etiotropic medicines against EBV is limited. The paper presents the anti-virus research of modified nucleoside with a wide spectrum of action - 6-azacytidine and its derivatives (2'-3'-seco-5-methyl-6-AC, 2',3'-dideoxy-2',3'-didehydro-6-AC and 2'-deoxy-6-AC) on the model of Epstein-Barr virus in Raji lymphoblastoid cells. Parameters of cytotoxicity (CC,) for the investigated substances were determined which amounted to 120 microg/ml, 180 microg/ml, 500 microg/ml, 330 microg/ml, and the effective concentration (ECU)--0.5 microg/ml. 1 microg/ml, 4 microg/ml, 11 microg/ml, in accordance with the sequence of preparations listed above. The results indicate a high antiEBV activity since their selectivity indexes (SI) were 240, 180, 125, 30 that is 1.3-10 times higher than the reference substance acycloguanosine. Apoptosis-stimulating action of 6-azacytidine and its derivatives was revealed. An increase of percentage of apoptotic cells in EBV-infected Raji cells and those treated with investigated substances as compared to uninfected ones was observed after 24 hours. Thus, our results provide new biological properties of the azacytidine substances.
S D
SD
Zagorodniaia
N V
NV
Nesterova
A V
AV
Golovan'
I V
IV
Alekseeva
L I
LI
Palchikovs'kaia
G V
GV
Baranova
D000212:Acyclovir / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000473:pathology / Q000821:virology; D002051:Burkitt Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004279:DNA, Viral / Q000032:analysis / Q000096:biosynthesis; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D020128:Inhibitory Concentration 50; D016133:Polymerase Chain Reaction; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D004279:DNA, Viral; D001374:Azacitidine; D000212:Acyclovir; C040881:6-azacytidine